Elsevier

Joint Bone Spine

Volume 80, Issue 2, March 2013, Pages 211-213
Joint Bone Spine

Case report
Two cases of Takayasu's arteritis occurring under anti-TNF therapy

https://doi.org/10.1016/j.jbspin.2012.07.015Get rights and content

Abstract

Takayasu's arteritis is a granulomatous, large vessel vasculitis that affects the aorta, its major branches and the pulmonary arteries. Compelling evidence exists to support the notion that Takayasu's arteritis is a T-cell mediated process and that tumor necrosis factor alpha (TNFa) is an important factor in the pathogenesis of this disease. Moreover, encouraging results from recent studies support the use of anti-TNFa therapy for relapsing or resistant cases of Takayasu's arteritis. Here, however, we describe the case of two patients: one with seropositive rheumatoid arthritis, the other with HLA-B27 negative spondylarthropathy, who developed Takayasu's arteritis during treatment with TNFa inhibitors (adalimumab and golimumab respectively). This is the first report of Takayasu's arteritis in rheumatic patients under TNFa blocking agents which suggests the presence of different pathogenetic mechanism in a subgroup of patients with Takayasu's arteritis, as well as a potential role of TNFa blockers as triggers of this disease in some cases.

Introduction

Takayasu arteritis is a rare, systemic large-vessel vasculitis of unknown aetiology that most commonly affects women of childbearing age. It is a granulomatous inflammatory disease that involves large- and medium-size arteries, with a predilection for the aorta and its branches. The association of Takayasu's arteritis and rheumatic diseases, including rheumatoid arthritis [1] and ankylosing spondylitis [2], [3], [4] has been described by several authors.

Tumor necrosis factor alpha (TNFa) is a cytokine involved in systemic inflammation, produced primarily by macrophages, but also by a broad variety of cell types including lymphoid cells, mast cells, endothelial cells; it promotes macrophage activation and lymphocyte trafficking and homeostasis. Since TNFa is implicated in other granulomatous diseases, its role in the pathogenesis of Takayasu's arteritis has been postulated and at least two large studies [5], [6] and several case reports [7], [8], [9] documented the efficacy of TNFa inhibitors (in particular the chimeric monoclonal antibody infliximab and the fusion protein etanercept) in cases of Takayasu's arteritis resistant to conventional glucocorticoid treatment.

In the present report, we describe two cases of Takayasu's arteritis in two patients with rheumatic diseases under treatment with TNFa inhibitors (rheumatoid arthritis treated with adalimumab and HLA-B27 negative spondylarthropathy treated with golimumab).

Section snippets

Case 1

A 43-year-old South American female patient formerly diagnosed with seropositive erosive rheumatoid arthritis in remission under treatment with adalimumab (40 mg biweekly since 5 years) and methotrexate (MTX, 25 mg weekly) was referred to our clinic with suspicion of Takayasu's arteritis. A thoraco-abdominal computerised tomography (CT-scan) was performed as part of a diagnostic investigation into persistently raised acute phase response in the absence of clinical signs or symptoms of active

Case 2

A 32-year-old female patient of Srilankan origin, diagnosed with a HLA-B27 negative spondylarthropathy with axial and peripheral manifestations, presented with a 3-week history of left arm claudication with weakness and local hypothermia.

Her recent clinical history was relevant only for type II diabetes treated with glicazide. Her spondylarthropathy (with axial and peripheral involvement) was treated with golimumab that was started recently (50 mg monthly, two doses) with a good clinical

Discussion

The treatment of relapsing or resistant Takayasu's arteritis with anti TNFa therapy has been proven effective in several case reports and two larger studies [5], [6], [10], [11]. However, autoimmune phenomena arising while patients are undergoing TNFa inhibition are all but rare and vasculitis, together with drug induced lupus, are the most common systemic manifestations [12], [13]. In most cases, vasculitis presents as a cutaneous manifestation, but renal, peripheral nerve system and lung

Conclusion

Our report is the first one to show the development of Takayasu's arteritis under treatment with TNFa inhibitors in patients with rheumatic diseases; retrospective analysis of large cohorts of patients under this drug class could help us to confirm a causative link and define subsets of patients susceptible of developing the disease.

Disclosure of interest

The authors declare that they have no conflicts of interest concerning this article.

References (15)

There are more references available in the full text version of this article.

Cited by (25)

  • Targeted treatment in Takayasu arteritis

    2022, Revue du Rhumatisme (Edition Francaise)
  • Increased incidence of spondyloarthropathies in patients with Takayasu arteritis: a systematic clinical survey

    2019, Joint Bone Spine
    Citation Excerpt :

    Recently, anti-TNF treatment has been placed on the agenda in TA patients as a treatment option. Interestingly in literature there are case reports of TA developing after initiation of these agents [32–34]. In these case reports two of three patients with SpA developed TA and the other one developed aortitis after treatment with anti-TNF agents.

  • Biological treatments in giant cell arteritis & Takayasu arteritis

    2018, European Journal of Internal Medicine
    Citation Excerpt :

    Concerning golimumab and certolizumab, no study reporting their use in TAK has been published. Furthermore, two cases of TAK occurring under anti-TNF-α therapy (adalimumab and golimumab, respectively) have been reported [31]. The French Takayasu Network recently reported on 49 TAK patients treated with biologics, of whom 35 received anti-TNF-α agents (28 infliximab [3–7 mg/Kg at W0, W2, W6 and then every 4–8 weeks], six received etanercept [25 mg twice a week], one received adalimumab [40 mg/2 weeks]) and 14 received tocilizumab (8 mg/Kg monthly).

View all citing articles on Scopus
View full text